General Information
Nintedanib esylate is a drug for the treatment of a lung disease called idiopathic pulmonary fibrosis (IPF). IPF may develop as a result of an aberrant wound-healing response in the lungs. Scar tissue replaces normal lung tissue, thickens and stiffens over time, compromising lung function, and resulting in progressive respiratory failure. In addition, nintedanib in combination with docetaxel is approved in Europe for the second-line treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor type. Adenocarcinoma is the most common type of lung cancer and many patients are diagnosed in an advanced stage.
About the API
- Japan DMF
- Korea DMF
- US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.